Anti-Human CD49D (Integrin alpha 4) (Natalizumab) [Hu114] – PE - 50 µg

Quality Tested by Leinco FC The suggested concentration for Natalizumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.

CD49D

Next Day 2 - 8°C

Natalizumab is characterized as a disease-modifying therapy for multiple sclerosis (a disease of the central nervous system (CNS)), and inflammatory bowel disease. It works by inhibiting the migration of leukocytes to inflammation sites. The VCAM-1 and α4β1-integrin interaction is necessary for leukocyte adhesion, firm attachment, and transmigration across the blood-brain barrier into the CNS. Natalizumab, a recombinant, humanized antibody, binds to α4β1 -integrin and blocks its interaction with VCAM-1. Hence, leukocyte migration into brain tissue is inhibited, thereby reducing inflammation and preventing the formation of multiple sclerosis lesions.1 Inflammation in the gut pertaining to inflammatory bowel disease can be controlled in a similar fashion. Blocking α4β7-integrin with a humanized, monoclonal antibody, specific to the α4β7 heterodimer inhibits the migration of leukocytes into the inflamed intestinal tissue, thus, reducing inflammation in the gut.2 This cost-effective, research-grade Anti-Human CD49D (Natalizumab) utilizes the same variable regions from the therapeutic antibody Natalizumab making it ideal for research projects.

B

Blue Laser (488 nm) and/or Green Laser (532 nm)/Yellow-Green Laser (561 nm)

HEK-293

Active

0.2 mg/ml

CD49D is a subunit of the integrin VLA-4, which is expressed on the cell surfaces of stem cells, progenitor cells, T and B cells, monocytes, natural killer cells, eosinophils, and neutrophils.

Research Use Only (RUO). Non-Therapeutic.

CD49D; alpha 4 subunit of VLA-4 receptor; ITGA4; Integrin alpha-IV, MS, multiple sclerosis, Inflammatory bowel disease, IBD, Ulcerative colitis, Crohn’s disease, IA4